These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32472525)

  • 61. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.
    Tovar N; Rodríguez-Lobato LG; Cibeira MT; Magnano L; Isola I; Rosiñol L; Bladé J; Fernández de Larrea C
    Amyloid; 2018 Jun; 25(2):79-85. PubMed ID: 29482381
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis.
    Bomsztyk J; Ravichandran S; Giles HV; Wright N; Berlanga O; Khwaja J; Mahmood S; Wisniowski B; Cohen O; Foard D; Gilbertson J; Rauf MU; Starr N; Martinez-Naharro A; Venneri L; Whelan C; Fontana M; Hawkins PN; Gillmore JD; Lachmann H; Harding S; Pratt G; Wechalekar AD
    Blood; 2024 Mar; 143(13):1259-1268. PubMed ID: 38194690
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis.
    Said SM; Sethi S; Valeri AM; Chang A; Nast CC; Krahl L; Molloy P; Barry M; Fidler ME; Cornell LD; Leung N; Vrana JA; Theis JD; Dogan A; Nasr SH
    Kidney Int; 2014 Aug; 86(2):370-7. PubMed ID: 24451324
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.
    Palladini G; Hegenbart U; Milani P; Kimmich C; Foli A; Ho AD; Vidus Rosin M; Albertini R; Moratti R; Merlini G; Schönland S
    Blood; 2014 Oct; 124(15):2325-32. PubMed ID: 25115890
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.
    Kastritis E; Gavriatopoulou M; Roussou M; Migkou M; Fotiou D; Ziogas DC; Kanellias N; Eleutherakis-Papaiakovou E; Panagiotidis I; Giannouli S; Psimenou E; Marinaki S; Apostolou T; Gakiopoulou H; Tasidou A; Papassotiriou I; Terpos E; Dimopoulos MA
    Am J Hematol; 2017 Jul; 92(7):632-639. PubMed ID: 28370245
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
    Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience.
    Cowan AJ; Skinner M; Seldin DC; Berk JL; Lichtenstein DR; O'Hara CJ; Doros G; Sanchorawala V
    Haematologica; 2013 Jan; 98(1):141-6. PubMed ID: 22733017
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
    Wong SW; Hegenbart U; Palladini G; Shah GL; Landau HJ; Warner M; Toskic D; Jaccard A; Hansen T; Bladé J; Cibeira MT; Kastritis E; Dispenzieri A; Wechalekar A; Varga C; Schönland SO; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e493-e499. PubMed ID: 30104177
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
    Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
    Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.
    Kastritis E; Papassotiriou I; Merlini G; Milani P; Terpos E; Basset M; Akalestos A; Russo F; Psimenou E; Apostolakou F; Roussou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas DC; Papadopoulou E; Pamboucas C; Dimopoulos MA; Palladini G
    Blood; 2018 Apr; 131(14):1568-1575. PubMed ID: 29386197
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
    Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immunofixation electrophoresis was highly specific for the diagnosis of renal light-chain amyloidosis.
    Zhou FD; Zhang LX; Yao Y; Wang SX; Zou WZ; Liu G; Chen M; Zhao MH
    Am J Med Sci; 2013 Jan; 345(1):18-21. PubMed ID: 22627261
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysis.
    Suzuki T; Kusumoto S; Yamashita T; Masuda A; Kinoshita S; Yoshida T; Takami-Mori F; Takino H; Ito A; Ri M; Ishida T; Komatsu H; Ueda M; Ando Y; Inagaki H; Iida S
    Ann Hematol; 2016 Jan; 95(2):279-85. PubMed ID: 26555284
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease.
    Abdallah AA; Alapat D; Kaur V; Atrash S
    J Oncol Pharm Pract; 2020 Jul; 26(5):1128-1133. PubMed ID: 31795821
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Individualized Approach to Management of Light Chain Amyloidosis.
    Palladini G; Milani P
    J Natl Compr Canc Netw; 2023 Jan; 21(1):91-98. PubMed ID: 36634608
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
    Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
    Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Instructions and implementations for percutaneous renal biopsy. Guidelines for the therapy of glomerular nephropaties].
    Cagnoli L;
    G Ital Nefrol; 2003; 20 Suppl 24():S3-47. PubMed ID: 14666502
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Retroperitoneal involvement with light chain amyloidosis- case series and literature review.
    Vaxman I; Visram A; Pasvolsky O; Kumar S; Dispenzieri A; Buadi F; Dingli D; Lacy M; Hayman S; Kyle R; Kapoor P; Leung N; Gonsalves W; Kourelis T; Warsame R; Gertz M
    Leuk Lymphoma; 2021 Feb; 62(2):316-322. PubMed ID: 33118418
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing.
    Muchtar E; Gertz MA; Kyle RA; Lacy MQ; Dingli D; Leung N; Buadi FK; Hayman SR; Kapoor P; Hwa YL; Fonder A; Hobbs M; Gonsalves W; Kourelis TV; Warsame R; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Rajkumar SV; Kumar SK; Dispenzieri A
    Mayo Clin Proc; 2019 Mar; 94(3):472-483. PubMed ID: 30770096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.